[{"id":"3a17035a-fef8-4bd4-80a2-7c5f2ca1ed3f","acronym":"Intellance1","url":"https://clinicaltrials.gov/study/NCT02573324","created_at":"2021-01-18T12:28:11.635Z","updated_at":"2024-07-02T16:35:48.205Z","phase":"Phase 3","brief_title":"A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification","source_id_and_acronym":"NCT02573324 - Intellance1","lead_sponsor":"AbbVie","biomarkers":" EGFR • MGMT","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • EGFRvIII mutation","tags":["EGFR • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • EGFRvIII mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • depatuxizumab mafodotin (ABT-414)"],"overall_status":"Completed","enrollment":" Enrollment 691","initiation":"Initiation: 01/04/2015","start_date":" 01/04/2015","primary_txt":" Primary completion: 04/04/2022","primary_completion_date":" 04/04/2022","study_txt":" Completion: 04/04/2022","study_completion_date":" 04/04/2022","last_update_posted":"2023-05-11"},{"id":"185a94cd-a349-4d14-992b-8bc9997567cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT02590263","created_at":"2021-01-18T12:34:17.164Z","updated_at":"2024-07-02T16:36:41.368Z","phase":"Phase 1/2","brief_title":"Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma","source_id_and_acronym":"NCT02590263","lead_sponsor":"AbbVie","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • depatuxizumab mafodotin (ABT-414)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 08/24/2015","start_date":" 08/24/2015","primary_txt":" Primary completion: 08/27/2020","primary_completion_date":" 08/27/2020","study_txt":" Completion: 08/27/2020","study_completion_date":" 08/27/2020","last_update_posted":"2020-09-03"},{"id":"be8c91be-539b-4b14-a9c2-42922b51a31c","acronym":"RTOG Foundation 3508","url":"https://clinicaltrials.gov/study/NCT02343406","created_at":"2021-01-18T11:08:20.656Z","updated_at":"2024-07-02T16:36:44.845Z","phase":"Phase 2","brief_title":"Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas","source_id_and_acronym":"NCT02343406 - RTOG Foundation 3508","lead_sponsor":"AbbVie","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • EGFRvIII mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • EGFRvIII mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lomustine • depatuxizumab mafodotin (ABT-414)"],"overall_status":"Completed","enrollment":" Enrollment 266","initiation":"Initiation: 02/17/2015","start_date":" 02/17/2015","primary_txt":" Primary completion: 06/24/2019","primary_completion_date":" 06/24/2019","study_txt":" Completion: 06/24/2019","study_completion_date":" 06/24/2019","last_update_posted":"2020-05-22"},{"id":"b45b7d7e-ea91-4655-9b1a-d36c708995e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03123952","created_at":"2021-01-18T15:23:35.910Z","updated_at":"2024-07-02T16:36:58.135Z","phase":"","brief_title":"Expanded Access to ABT-414","source_id_and_acronym":"NCT03123952","lead_sponsor":"AbbVie","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • EGFRvIII mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • EGFRvIII mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e depatuxizumab mafodotin (ABT-414)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2019-07-15"},{"id":"3ecdc7a7-9b27-4431-a827-8db514545d34","acronym":"","url":"https://clinicaltrials.gov/study/NCT01800695","created_at":"2021-01-18T07:58:14.654Z","updated_at":"2024-07-02T16:37:16.125Z","phase":"Phase 1","brief_title":"Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme","source_id_and_acronym":"NCT01800695","lead_sponsor":"AbbVie","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification • EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • depatuxizumab mafodotin (ABT-414)"],"overall_status":"Completed","enrollment":" Enrollment 202","initiation":"Initiation: 04/02/2013","start_date":" 04/02/2013","primary_txt":" Primary completion: 06/19/2017","primary_completion_date":" 06/19/2017","study_txt":" Completion: 06/19/2017","study_completion_date":" 06/19/2017","last_update_posted":"2017-11-21"},{"id":"fc2221ae-5b3f-4672-9045-b9945c90127f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01741727","created_at":"2021-01-18T07:37:25.208Z","updated_at":"2024-07-02T16:37:16.222Z","phase":"Phase 1/2","brief_title":"A Study of ABT-414 in Subjects With Solid Tumors","source_id_and_acronym":"NCT01741727","lead_sponsor":"AbbVie (prior sponsor, Abbott)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification • EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e depatuxizumab mafodotin (ABT-414)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 11/01/2015","primary_completion_date":" 11/01/2015","study_txt":" Completion: 11/01/2015","study_completion_date":" 11/01/2015","last_update_posted":"2017-11-20"}]